Acetylcysteine

Generic Name: Acetylcysteine

Brand Names: Acetadote

Drug Type: Small Molecule

Chemical Formula: C_₅H_₉NO_₃S

CAS Number: 616-91-1

Unique Ingredient Identifier: WYQ7N0BPYC

Background: Acetylcysteine is an antioxidant and glutathione inducer indicated for mucolytic therapy and the treatment of acetaminophen overdose. Acetylcysteine has also been studied for a wide variety of off-label indications with mixed results.

Acetylcysteine was granted FDA approval on 14 September 1963.

Indication: Acetylcysteine is indicated for mucolytic therapy and in the management of acetaminophen overdose.

Associated Conditions: Acetaminophen Overdose, Chronic Rhinitis, Corneal Diseases, Corneal ulceration, Crusting Rhinitis, Keratopathy, Rhinitis, Sinusitis, Vasomotor Rhinitis, Acute Rhinitis, Subacute Rhinitis

Associated Therapies: Airway secretion clearance therapy

Clinical Trials

The Combination of Atorvastatin, Acetylcysteine and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia

Phase 1

Conditions: Immune Thrombocytopenia

Interventions: Drug: atorvastatin
Drug: Acetylcysteine
Drug: Danazol

First Posted Date: 2018-03-09

Last Posted Date: 2018-03-09

Lead Sponsor: Peking University People's Hospital

Target Recruit Count: 200

Registration Number: NCT03460808

Locations: 🇨🇳
Peking University Insititute of Hematology, Peking University People's Hospital, Beijing, Beijing, China

Efficacy of N-acetylcysteine on the Craving Symptoms of Abstinent Hospitalized Patients With Cocaine Addiction

Phase 2

Recruiting

Conditions: Cocaine Addiction

Interventions: Drug: Lactose powder
Drug: N-acetylcysteine

First Posted Date: 2018-02-06

Last Posted Date: 2024-08-06

Lead Sponsor: Salvatore Campanella

Target Recruit Count: 80

Registration Number: NCT03423667

Locations: 🇧🇪
CHU Brugmann, Brussels, Belgium

A Safety and Efficacy Study of NAC in Patients With TA-TMA

Phase 3

Completed

Conditions: Thrombotic Microangiopathies
Hematologic Diseases

Interventions: Drug: Placebo Oral Tablet
Drug: N-Acetylcysteine

First Posted Date: 2017-08-17

Last Posted Date: 2022-02-14

Lead Sponsor: The First Affiliated Hospital of Soochow University

Target Recruit Count: 170

Registration Number: NCT03252925

Locations: 🇨🇳
The First affiliated Hospital of SooChow University, Suzhou, Jiangsu, China

Neuroscience-Informed Treatment Development for Adolescent Alcohol Use

Phase 2

Completed

Conditions: Alcohol Drinking
Control

Interventions: Drug: N-Acetylcysteine
Drug: Placebo Oral Capsule

First Posted Date: 2017-08-03

Last Posted Date: 2023-06-22

Lead Sponsor: Medical University of South Carolina

Target Recruit Count: 57

Registration Number: NCT03238300

Locations: 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States

Effect of NAC on the Hematopoietic Reconstitution After Haploidentical Hematopoietic Stem Cell Transplantation

Phase 2

Completed

Conditions: Haploidentical Hematopoietic Stem Cell Transplantation

Interventions: Drug: N-acetyl-L-cysteine

First Posted Date: 2017-08-01

Last Posted Date: 2020-09-17

Lead Sponsor: Peking University People's Hospital

Target Recruit Count: 35

Registration Number: NCT03236220

Locations: 🇨🇳
Peking University People's Hospital, Beijng, China

N-acetylcysteine for the Treatment of Cannabis Dependence: Working Mechanisms

Phase 4

Conditions: Cannabis Use Disorder
Cannabis Dependence

Interventions: Drug: Placebo Oral Tablet
Drug: N-acetylcysteine
Other: Magnetic Resonance Imaging
Other: Neurocognitive measures
Other: Neuro-inflammatory measures

First Posted Date: 2017-07-18

Last Posted Date: 2020-12-08

Lead Sponsor: Universitair Ziekenhuis Brussel

Target Recruit Count: 75

Registration Number: NCT03221231

Locations: 🇧🇪
University Hospital Brussels, Brussels, Belgium

Imaging GABAergic/Glutamatergic Drugs in Bipolar Alcoholics Alcoholics

Phase 2

Completed

Conditions: Bipolar Disorder
Alcohol Use Disorder

Interventions: Drug: N-Acetylcysteine
Drug: Gabapentin
Drug: Placebo Oral Tablet

First Posted Date: 2017-07-18

Last Posted Date: 2023-12-13

Lead Sponsor: Medical University of South Carolina

Target Recruit Count: 54

Registration Number: NCT03220776

Locations: 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States

PP100-01 (Calmangafodipir) for Overdose of Paracetamol

Phase 1

Completed

Conditions: Paracetamol Overdose

Interventions: Drug: PP100-01 (calmangafodipir)
Drug: Acetylcysteine

First Posted Date: 2017-06-06

Last Posted Date: 2019-10-03

Lead Sponsor: Egetis Therapeutics

Target Recruit Count: 24

Registration Number: NCT03177395

Locations: 🇬🇧
Royal Infirmary of Edinburgh, Edinburgh, City Of Edinburgh, United Kingdom

N-Acetylcysteine and L-carnitine in Pcos

Phase 2

Completed

Conditions: PCOS

Interventions: Drug: N-Acetylcysteine
Drug: L-carnitine

First Posted Date: 2017-05-23

Last Posted Date: 2018-09-18

Lead Sponsor: Zagazig University

Target Recruit Count: 164

Registration Number: NCT03164421

Locations: 🇪🇬
Zagazig University, Zagazig, Egypt

"Multimodal Prevention of Psychosis - Investigating Efficacy of N-Acetylcysteine and Psychotherapy in CHR-Patients"

Phase 3

Terminated

Conditions: Prodromal Schizophrenia

Interventions: Drug: Placebo
Drug: N-Acetylcysteine
Behavioral: PSM (Psychological stress management)
Behavioral: IPPI (Integrated Preventive Psychological Intervention)

First Posted Date: 2017-05-11

Last Posted Date: 2022-05-09

Lead Sponsor: University Hospital, Bonn

Target Recruit Count: 48

Registration Number: NCT03149107

Locations: 🇩🇪
Uniklinikum Bonn, Bonn, Nordrhein-Westfalen, Germany
🇩🇪
LVR Klinik Düsseldorf, Düsseldorf, Nordrhein-Westfalen, Germany
🇩🇪
Universitätsklinik Tübingen, Tübingen, Baden-Württemberg, Germany

and more 7 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy